About the
M17-380 Study

After establishing initial eligibility, study participants will be assigned randomly (by chance) to receive either the investigational product (a tablet taken by mouth) or the comparator product, a product that’s already been tested in children in this age group with atopic dermatitis (which will be given as an injection under the skin). Your child will be able to take the investigational product as an oral solution if they cannot swallow a tablet. Participants who have previously taken the comparator product and have not seen improvement will be automatically assigned to receive the investigational product.

Participants taking the investigational product may also be asked to participate in an optional substudy (a study within the study) to test how the investigational product impacts the effectiveness of certain vaccines, which will be given as injections into the skin. Only children already scheduled to receive these vaccines from another licensed healthcare provider are eligible to participate in the substudy.